top of page

Dott.ssa Silvia Pelligra
medico specialista in ginecologia e ostetricia

Esperienza Lavorativa

August 2012
30 days Professional Exchange program IFMSA Department of Gynecology and Obstetrics Chelyabinsk Hospital 6, Russia

September 2015
30 days Professional Exchange program IFMSA Department of Gynecology and Obstetrics St. George Hospital Beirut, Lebanon

Nov 2015- Feb 2016
1000 hours of practise in general medicine and operating room. University of Catania

June 2016- Sept 2016
Work as emergency doctor Medical ward of Fondachello, Catania, Italy


1 st Sept 2019- 31 th March 2020
Postdoctoral Research Fellowship in Gynecologic Oncology, Department of Gynaecologic Oncology. Yale University New Haven, US


1 St Dec 2021- on going

Medical Doctor as Gynecologist Policlinico A. Gemelli IRCCS Rome, Italy

Formazione ed Istruzione


20 th July 2015
Master Degree in Medicine and Surgery University of Catania 110/110 cum laude

Catania, Italy

15 th Feb 2016
Professional license to practice Medicine and Surgery University of Catania
Catania, Italy

1 st Nov 2016– 26 th Oct 2021
Residency in Obstetrics and Gynecology Department of Women's and Children's Health IRCCS Catholic University of Sacred Heart Rome, Italy

01 st Dec 2021- on going
International Master in Minimally invasive gynaecological surgery
Catholic University of Sacred Heart Rome, Italy


1. Robotic versus laparoscopic radical hysterectomy in early cervical cancer: a
case matched control study. Gallotta V, Conte C, Federico A, Vizzielli G,
Gueli Alletti S, Tortorella L, Pedone anchora L, Cosentino F, Chiantera V,
Fagotti A, D’indinosante M, Pelligra S., Scambia G, Ferrandina G. Eur J
Surg Oncol. 2018 Feb 5. pii: S0748-7983(18)30129-X. doi:

2. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse
survival by pattern of recurrence and secondary treatment. Legge F,
Restaino S, Leone L, Carone V, Ronsini C, Di Fiore GLM, Pasciuto T,
Pelligra S, Ciccarone F, Scambia G, Fanfani F. Int J Gynecol Cancer. 2020
Feb;30(2):193-200. doi: 10.1136/ijgc-2019-000822. Epub 2019 Dec 1.

3. Comparison of minimally invasive surgery with laparotomic approach in the
treatment of high risk endometrial cancer: A systematic review. Scaletta G,
Dinoi G, Capozzi V, Cianci S, Pelligra S, Ergasti R, Fagotti A, Scambia G,
Fanfani F. Eur J Surg Oncol. 2019 Dec 2. pii: S0748-7983(19)31468-4. doi:

4. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate
Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active
Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Perrone E, Lopez S,
Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A,
Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C,
Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia
G, Santin AD. Front Oncol. 2020 Feb 12;10:118. doi: 10.3389/fonc.2020.00118. eCollection 2020.

5. Selection of HER2/NEU negative tumor cells as a mechanism of resistance
to trastuzumab in uterine serous carcinoma. Pelligra S, Buza N, Hui P,
Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD.
Gynecol Oncol Rep. 2020 Feb 25;32:100554. doi: 10.1016/j.gore.2020.100554. eCollection 2020 May.

6. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET
bromodomain inhibitor GS-626510 in uterine cervical carcinoma. E.
Bonazzoli, S. Bellone, L. Zammataro, B. Gnutti, A. Guglielmi, S. Pelligra,
Alessandro D Santin. Gynecol Oncol 2020 Sep;158(3):769-775. doi:
10.1016/j.ygyno.2020.06.484. Epub 2020 Jun 26.

7. Diagnostic accuracy and economic impact of three work-up strategies
identifying risk groups in endometrial cancer, fully incorporating sentinel
lymph node algorithm. A. A. Novelli, A. Puppo, M. Ceccaroni, E Olearo, G
Monterossi, G. Mantovani, S. Pelligra, P. L. Olearo, F. Fanfani., G.
Scambia. Facts Views Vis Obgyn. 2020 Oct 8;12(3):169-177.

8. Update on new imaging technologies in sentinel node detection. Pelligra S,
Scaletta G, Cianci S, Gueli Alletti S, Restaino S, Fagotti A, Scambia G,
Fanfani F. Minerva Ginecol. 2020 Dec;72(6):404-412. doi: 10.23736/S0026-
4784.20.04707-3. Epub 2020 Dec 11. PMID: 33306284.

9. Update on the secondary cytoreduction in platinum-sensitive recurrent
ovarian cancer: a narrative review. Conte C, Fagotti A, Avesani G,
Trombadori C, Federico A, D'Indinosante M, Giudice MT, Pelligra S, Lodoli
C, Marchetti C, Ferrandina G, Scambia G, Gallotta V. Ann Transl Med. 2021
Mar;9(6):510. doi: 10.21037/atm-20-4690. PMID: 33850907; PMCID:

10. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly
active against uterine serous carcinomas in vitro and in vivo. Tymon-
Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A,
Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J,
Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M,
Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD.
Gynecol Oncol. 2021 Aug 24:S0090-8258(21)01313-5. doi: 10.1016/j.ygyno.2021.08.014. Epub ahead of print. PMID: 34452746.

11. Clinical impact of integrated molecular-based risk assessment of early-
stage endometrial cancer: a propensity score matched analysis. Camilla
Nero, Tina Pasciuto, Serena Cappuccio, Giacomo Corrado, Silvia Pelligra,
Gian Franco Zannoni, Angela Santoro, Alessia Piermattei, Angelo Minucci,
Domenica Lorusso, Francesco Fanfani, G. Scambia. (SUBMITTED) (ID:

bottom of page